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Clostridium difficile (CD) infections are a growing threat due to the strain resistance to antibiotic 
treatment and the emergence of hypervirulent strains. One solution to this problem is the search for 
new vaccine antigens, preferably surface-localized that will be recognized by antibodies at an early 
stage of colonization. The purpose of the study was to assess the usefulness of novel immunoreactive 
surface proteins (epitopes) as potential vaccine antigens. Such approach might be tough to pursue since 
pathogens have acquired strategies to subvert adaptive immune response to produce humoral response 
against non-essential proteins for their survival. In this study CD surface proteins were isolated, 
immunoreactive proteins identified and mapped to select potential epitopes. The results of the study 
exclude the use of CD glyceraldehyde 3-phosphate dehydrogenase as a vaccine antigen, especially as 
a whole protein. Sequences P9 (201AAGNIVPNTTGAAKAI218) and P10 (224KGKLDGAAQRVPVVTG241) 
recognized by patients sera are conserved and widespread among CD strains. They show cross-
reactivity with sera of people suffering from other bacterial infections and are recognized by sera of 
autoimmune disease patients. Our study documents that special care in analyzing the sequence of new 
epitope should be taken to avoid side effects prior to consider it as a vaccine antigen.
Designing new microbiological vaccines is a complicated and risky process due to the fact that microorgan-
isms use devious techniques of avoiding the immune system. One of the basic mechanisms is changing the 
expression of antigens present on the surface of the pathogen named as immunological decoy1. As an example, 
Mycobacterium tuberculosis (Mtb) expresses Ag85b at a high level at the beginning of infection which leads to T 
cell response against this protein. When the infection establishes Mtb switches off Ag85b expression and T cell 
response is no longer a threat2. Another strategy is to introduce point mutations in antibody-binding regions3. 
Above tactics cause the use of proteins as a vaccine antigen extremely difficult. One of the proposed solutions is 
to use conserved and essential proteins.
Glyceraldehyde-3-phosphate dehydrogenase EC 1.2.1.12 (GAPDH) is one of the essential proteins taking part 
in glycolysis, present in almost all organisms. Recent reports show that this is not the only role and that it possess 
many other functions like cell signaling, interaction with other proteins, control of gene expression and also 
takes part in microbial virulence4. The protein is no longer considered as solely intracellular, it might be secreted 
on the cell surface and plays its additional roles as a moonlighting protein. GAPDH is present on the surface 
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of Gram-positive pathogenic strains where it takes part in colonization and manipulation of host cells5. It can 
bind fibronectin, lysozyme, laminin, cytoskeletal proteins6, interact with human plasminogen, helps adhesion to 
pharyngeal cells7, also can support escaping host immune system8. Identification of so many new functionalities, 
especially in pathogenic microorganisms, leads to the suggestion that GAPDH might be a suitable vaccine candi-
date since it is essential for pathogen viability. It was proposed as vaccine antigen against Schistosoma mansoni9, 
Edwardsiella tarda10 and Streptococcus pneumoniae11. So far, the possibility of using GAPDH as a CD vaccine 
antigen has not been studied.
There are advantages and disadvantages of GAPDH being such a widespread protein. It was already proposed 
as a suitable candidate for multivalent vaccine antigen against microbial infection in aquaculture12. But, from 
the other side, it was suggested that because of GAPDH high sequence homology between bacterial strains and 
human it should be carefully analyzed for possible autoimmunoreactivity13 since it could lead to autoimmune dis-
ease. GAPDH is already reported as a protein implicated in numerous autoimmune disorders. GAPDH-reactive 
autoantibodies were found in the Cerebrospinal Fluid (CSF) of patients with multiple sclerosis14. Autoantibodies 
to GAPDH were also reported in CSF of patients with lupus15. The mechanism which leads to production of these 
autoantibodies is still unknown but recently, some authors suggested that these autoantibodies can be primarily 
initiated by T and B cells reacting to foreign GAPDH, present on the surfaces of parasites, bacteria and fungi16,17.
The aim of these studies was to evaluate the effectiveness of immunoreactive surface antigens from Clostridium 
difficile (CD) as potential vaccine antigens. CD is a Gram-positive, strictly anaerobic, spore-forming bacte-
rium that is widely recognized as one of the most common causes of hospital acquired infections. It can cause a 
wide range of diseases from mild antibiotic-associated diarrhea (AAD) to severe pseudomembranous colitis in 
immunocompromised patients18. The increase of severity and frequency of Clostridium difficile infections (CDI) 
over last few years makes the need for protective and therapeutic vaccines more urgent. In the current research 
GAPDH was identified as an immunoreactive protein reacting with antibodies from umbilical cord blood sera 
collected from mothers without the signs of CDI. GAPDH sequence was thoroughly analyzed in silico which 
resulted in a selection of potentially immunoreactive epitopes in the form of 16-mer peptides which were synthe-
sized and mapped using PEPSCAN method and ELISA. Peptides were tested for immunoreactivity using blood 
sera from CD infected patients resulting in two potential epitopes. Those two epitopes were further investigated 
to exclude cross-reactivity with other pathogenic and non-pathogenic species, and autoimmunoreactivity.
Results
GAPDH is an immunoreactive protein recognized by umbilical cord blood sera. Proteins isolated 
from CD with 1 M LiCl were separated using SDS-PAGE and their immunoreactivity was analyzed by Western 
blotting. The electrophoresis profile is consistent with previous experiments performed with C. difficile 63019 
(Fig. 1) which belongs to the 027 ribotype. However, a novel approach was used to search for new immunoreac-
tive proteins which is the use of umbilical cord blood sera. This method is routinely used in our laboratory20,21. It 
revealed a set of immunoreactive proteins (Fig. 1). A band that corresponds to a mass of 37 kDa was excised and 
analyzed by LC-MS/MS. Protein was identified by comparison of peptides masses in UniProt database (NCBI) 
using MASCOT and statistical analysis. One of the identified proteins was assigned as type I glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) with a molecular mass of 36.2 kDa, pI 5.72, identified with high coverage 
of 77% and identification score of 8757 (Fig. 1). The second protein found in the same gel band was also identified 
as GAPDH Type I but with slightly different pI and lower identification score.
Sequence analysis between 50 different strains of CD shows that GAPDH occurs as two types and both types 
are conservative between toxigenic and non-toxigenic CD strains (data not shown). The structure of CD GAPDH 
is unknown, so that a structural model was built based on a template sequence appointed by BLAST. The struc-
ture model of GAPDH was prepared based on sequence with 74.55% identity which is Streptococcus agalactiae 
GAPDH (template: 5jyf.1.A). The protein was modeled as a homotetramer, with no ligands. It is composed in 
26% of α-helix, 23% of β-strands and 51% of loops (Fig. 2). Detailed bioinformatics analysis showed that there are 
Figure 1. Results of protein isolation and identification. Proteins were extracted using 1 M LiCl, separated 
in 12,5% gels SDS-PAGE and silver-stained, lane 2. Separated proteins were analyzed by Western blot using 
umbilical cord blood pooled sera, lane 3. Full-length uncropped gel and blot are included in Supplementary 
Figs 1 and 2. The white box indicate band selected for MS/MS identification. Results of protein identification are 
showed in the table on the right.
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not known signal peptides in the protein sequence and that localization is predominantly cellular. This structural 
characteristics was exploited in planning peptides for epitope mapping.
Clostridium difficile GAPDH as a moonlighting protein. To our knowledge there are no reports about 
possible alternative role of GAPDH in CD. We performed detailed analysis of GAPDH sequence using available 
bioinformatics tools and compared obtained results with known physical features of intracellular proteins that 
moonlight on the cell surface22. Most of the moonlighting proteins does not have signal sequence, they com-
prise of 200–800 amino acids with theoretical pI between 4.5 and 6.5 and the Grand Average of Hydropathy 
(GRAVY) score of moonlighting proteins is negative or zero. CD GAPDH meets all of the above criteria (Fig. 2). 
CD GAPDH comprises of 335 amino acids with theoretical pI of 5.72 and GRAVY score of −0.0636. We per-
formed sequence alignment of GAPDH from CD and moonlighting GAPDH from various strains gathered in 
Supplementary Table S1. The percent identity created by Clustal2.1 ranged from 55.32% for Bacillus anthracis 
GAPDH up to 75.15% for Streptococcus species which indicates high sequence similarity between some strains 
that have moonlighting GAPDH. To sum up, since we have identified GAPDH in the mixture of surface proteins, 
obtained by a gentle wash-off method19 and the protein have similar characteristics of moonlighting proteins and 
shares with them high sequence similarity we suggest that GAPDH from CD might be one of the moonlighting 
proteins.
Epitope mapping using CDI patient sera reveals highly immunoreactive peptide sequences. 
Based on structural model of CD GAPDH (Fig. 2) and bioinformatics analysis of B-cell and T-cell linear epitopes 
we qualified 20 peptides 16-amino acids long for PEPSCAN synthesis and mapping (Fig. 3). Pin-bound pep-
tide ELISA with pooled CDI patient sera showed various peptide activity. Two peptides, which are named as 
numbers 9 (201AAGNIVPNTTGAAKAI218, P9) and 10 (224KGKLDGAAQRVPVVTG241, P10) have the highest 
Figure 2. Model of GAPDH and sequence characteristics. Model was prepared based on sequence with 74.55% 
identity which was Streptococcus agalactiae GBS GAPDH (template: 5jyf.1.A).
Figure 3. The design of peptides selected for mapping. Figure shows C. difficile GAPDH sequence and peptide 
sequences that were considered for mapping - identified by software as probable epitopes. Empty ovals – B-cell 
epitopes; shaded ovals – T-cell epitopes; rectangles – sequences in exposed loops. Sequences indicated by arrows 
are the one selected for chemical synthesis.
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immunoreactivity (Fig. 4A), they were 10 to 11 times more active than non-active peptides (peptides of absorb-
ance less than 1). Both epitopes were selected as potential B cell epitopes and their fragments as T cell epitopes 
during in silico analysis. The localization within the protein of peptides P9 and P10 is shown on Fig. 4B. There are 
also two less active peptides numbers 8 and 16, which activity is 5.5 and 8 time more than non-active peptides. We 
decided to focus on P9 and P10 in next experiments, also we selected peptide number 5 as a non-active control 
(115KVVISAPATGDLKTIV132, P5).
Peptides 9 and 10 contain common epitopes. We compared GAPDH sequences of virulent strains 
that are known to express moonlighting GAPDH with CD protein (Fig. 5). The percent of identity varies from 
45.26% for Staphylococcus aureus up to 75.15% in case of Streptococcus pyogenes GAPDH which implicates high 
variability in the protein sequence between virulent strains. In the next step we compared sequences of GAPDH 
peptides that were the most reactive with CDI patient sera. We found out that P9 comprise 13/16 (81.25%) 
unchanged amino acids in case of most homologic Streptococcus pyogenes and 8/16 (50%) unchanged amino 
acids for the most different strain which is Staphylococcus aureus. P10 comprises of 14/16 (87.5%) of the same 
amino acids in case of most homologic Streptococcus pyogenes and 8/16 (50%) unchanged amino acids for the 
most different strain which is Staphylococcus aureus. Surprisingly in the case of control peptide P5, which did 
not react with patient sera the ratio of unchanged amino acid is 10/16 (62.5%) for most similar strain which is 
Streptococcus pyogenes and 4/16 (25%) for most different strain which is Staphylococcus aureus. The above finding 
suggests that immunoreactive GAPDH peptide sequences P9 and P10 remain better preserved between strains 
than non-reactive peptide P5.
We confronted P9 and P10 with corresponding regions in GAPDH of strains from human gut physiologic 
microflora in order to verify if these peptides are widely distributed among bacterial strains. The degree of 
sequence preservation does not diverge from that of the pathogenic strains. The above data show that both immu-
noreactive sequences are very well conserved in pathogenic and non-pathogenic strains. It is easy to distinguish 
100% compatible sequences such as TGAAKAI (P9) that occurs in all tested strains, regardless of homology, or 
GKLxGxAxRVP (P10), which are long enough to be epitopes. The control peptide P5 is characterized by much 
greater variability.
We compared CD GAPDH with similar protein of human origin and from mouse which is the most utilized 
animal model (Fig. 5). Again, we can distinguish a 6-mer identical sequence (TGAAKA) in P9 overlapped by 
amino acids belonging to the same subgroup (Thr-Ser are both polar uncharged amino acids; Ile and Val are both 
hydrophobic) which increases the length of potential epitope to 8 amino acids. We identified in P10 a conserva-
tive region composed of 11 amino acids with two 3-mers identical to human sequences (GKL and RVP). Three 
amino acid sequences are most probably too short to be epitopes since shortest known epitopes are 5–6 amino 
acid long. However, three amino acids can work as a core for antibody binding or a ‘functional epitope’ with other 
amino acids supporting the binding23.
Peptides 9 and 10 show cross-reactivity. In order to analyze cross-reactivity of P9 and P10 with sera 
immunized with other pathogens we performed ELISA using umbilical cord blood sera samples from patients 
Figure 4. Results of epitope mapping using pooled sera from CDI patients (n = 10). (A) shows results of ELISA 
performed using peptides bound to the pins on 96 well plate. Primary antibody was detected by anti-human 
IgG-AP conjugated goat antibody which reacts with AP Yellow substrate. The result of colorimetric reaction was 
measured by reading absorbance in 405 nm. The figure shows results from three independent measurements, 
means with SD. (B) shows the localization of peptides P9 and P10.
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diagnosed with group B streptococcus infection (Streptococcus agalactiae). Pooled umbilical cord blood sera 
samples from healthy volunteers (not diagnosed with GBS) were used as controls (healthy controls, n = 10). 
Experiment shows that reactivity of both peptides is significantly higher for GBS+ patients in comparison to 
healthy controls (GBS−) (Fig. 6A).
The analysis performed for individual patient sera shows that reactivity of P9 is significantly higher for 2 out 
of 3 of GBS+ patients in comparison to healthy control. Sera KP17 and KP31 were obtained from GBS− patients 
but with diagnosed accompanying diseases (KP17 – diabetes and Hashimoto disease, KP31 - von Willebrand 
disease), both show higher reactivity albeit not statistically significant when 2way ANOVA was used (Fig. 6B). 
The same outcome was observed for P10 analyzed with GBS+ and GBS− sera but with higher overall reactivity 
(Fig. 6C).
Human sera IgG antibodies from autoimmune patients recognize epitopes of P9 and P10. 
What we are particularly interested in is the high degree of conservation of P9 and P10 sequences in very distant 
phylogenetic species such as CD and human or mouse. Despite of low homology between CD GAPDH and 
human GAPDH (44.5%) 10 out of 16 amino acids in sequence P9 are preserved and 8 out of 16 for P10 sequence, 
while with control peptide P5 only 6 out of 16 (Fig. 5). For this reason, we have decided to examine the possible 
relationship between these sequences and autoimmunity. We performed search in Immune Epitope Database and 
Analysis Resource (IEDB) in order to verify if P9 and P10 contain known epitopes. We were looking for epitope 
content with no less than 70% identity. The search was not restricted to any host, assay, MHC type nor disease. 
Results showed that fragments of P9 sequence can be found in 32 known autoepitopes, in 9 different antigens, 
from 5 different hosts. They were found mostly in human and mouse GAPDH. Anti-GAPDH autoantibodies 
specific for sequences included in peptide 9 were reported in systemic lupus erythematosus15 and were found in 
cerebrospinal fluid of patients with multiple sclerosis14. Fragments of P10 can be found in nucleoprotein of influ-
enza A virus, but so far there are no known-autoepitopes in P10 sequence or verified autoantibodies.
We performed autoreactivity analysis of P9 and P10 using sera from patients with autoimmune disorder which 
is Graves disease (Fig. 7), an autoimmune disorder with combined still not fixed genetic/environmental origin24. 
Analysis of P9 and P10 peptides with sera from Graves’ patients (pooled, n = 10) shows elevated reactivity for 
both peptides in comparison with sera from healthy volunteers (pooled, n = 21). Also individual patient serum 
samples were analyzed. In case of P9 sera from two out of three patients show statistically significant difference in 
reactivity in comparison to healthy control. In case of P10 serum from one out of three patients show statistically 
significant difference in reactivity in comparison to healthy control. The rest of individual patient samples show 
higher reactivity with both peptides in comparison to healthy controls but it is not statistically significant when 
2way ANOVA test is used. These results show that sera from autoimmunized patients specifically recognize both 
CD GAPDH peptides.
Discussion
Finding new ways to fight Clostridium difficile (CD) is essential because of the increasing strains virulence and 
resistance to routine treatment. One way is to design an effective vaccine. At the present, there are several anti-CD 
vaccines in development based on toxins A and B25. There is also urgent need for new antigens for vaccine, pref-
erably present on the cell surface, which would allow to wipe out the pathogen at the early stage of the disease, 
that is, at the time of colonization, before the pathogen even begins to produce toxins. The best solution would 
be to use an immunoreactive multifunctional protein critical for the bacteria survival. By using this strategy it 
Figure 5. Alignment of Clostridium difficile GAPDH peptide sequences and GAPDH from other species. % 
identity of GAPDH sequences compared to Clostridum difficile GAPDH sequence. Amino acids in the red are 
the one shared with C. difficile and selected strains. Sequences in the frames are most conservative between 
strains. Selected strains include human, mouse, pathogenic strains that express moonlighting GAPDH and most 
prevalent strains from gut flora.
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might be possible to prevent decoy effect and protein mutation which are used by bacteria as a strategy of escaping 
immune response.
The search for CD new vaccine antigens was major purpose of these studies. It started with isolation of surface 
proteins by gentle ‘washing off ’ from bacterial cell surface without its damaging. The isolate consists primarily of 
surface proteins19. Clinical strains used for the purpose of protein isolation were collected from patients to take 
into account currently occurring ribotypes. Western blotting analysis was performed using umbilical cord blood 
sera from patients without the symptoms of CDI. The use of umbilical blood sera to identify new cross-reactive 
proteins with other pathogens have been practiced in our Laboratory for years20,26. As the transmission of 
Figure 6. Reactivity of GBS positive umbilical cord blood sera with C. difficile peptides P9 and P10. (A) shows 
mean value obtained for sera GBS+ and GBS− for both peptides. (B) shows data for individual patients GBS+ 
and GBS− (healthy controls and women with other diseases) obtained for peptide P9. (C) shows data for 
individual patients GBS+ and GBS− (healthy controls and women with other diseases) obtained for peptide 
P10. All figures show data from at least three independent measurements, means with SD, data analyzed with 
2way ANOVA *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 7. Reactivity of sera from patients with autoimmune disease with C. difficile peptides P9 and P10. Figure 
shows results from at least three independent measurements, means with SD, data was analyzed using 2way 
ANOVA *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
www.nature.com/scientificreports/
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antibodies from mother to the baby is highly regulated and selective process27, and therefore the transferred 
antibodies have extraordinary protective potential. Results of our own study conducted on umbilical cord blood 
and peripheral blood sera have shown differences in profiles of recognized proteins26. For example, it has been 
shown that a natural and effective factor in protecting infants from infection is provided by IgG class antibodies, 
directed against GBS (group B streptococci) surface antigens, transferred from mother’s blood to the placenta28. 
Maternal IgG antibodies are partially or fully protective against respiratory syncytial virus and influenza virus in 
humans29,30. A vaccine consisting of epitopes recognized by antibodies passed from the mother could be highly 
protective. This is an alternative that can bring more benefits than using sera samples only from patients during 
active illness. Using this method we identified a set of immunoreactive proteins. One of them was assigned as 
type I glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH was already proposed as a suitable vaccine 
antigen for other pathogens9,10 so we decided to analyze in detail the possibility of its application in vaccine.
GAPDH was considered to be a housekeeping protein of intracellular localization with metabolic functions 
essential for almost all organisms. Recent reports show that it might serve as a moonlight protein in various 
bacterial species (Supplementary Table S1) which means it is multifunctional and can exhibit alternative cellular 
localization. Most important from the virulence point of view is that GAPDH can bind plasminogen, mucin and 
fibrinogen by which can act as an adhesion molecule. We performed analysis of CD GAPDH protein sequence, its 
biochemical properties as well as in silico modeling (Fig. 2). As a result of our study we suggest that CD GAPDH 
is a moonlighting protein since the protein has been isolated with LiCl surface protein isolation method, has fea-
tures typical for moonlighting proteins (similar sequence length, GRAVY score, theoretical pI), and displays high 
homology with such proteins isolated from other strains gathered in Table S1. Although, this suggestion should 
be supported by additional experiments. Many moonlighting proteins fulfill additional functions, very often are 
directly associated with virulence and can be located on the surface of the cell where the therapeutic antibodies 
are readily accessible which justify the usage of such proteins as an vaccine antigens. Moonlighting properties of 
CD GAPDH should be further investigated since it might be important for CD virulence.
Epitope mapping of CD GAPDH using sera from patients with CDI revealed two highly immunoreactive 
peptides P9 and P10, which were further investigated for cross-reactivity and autoimmunoreactivity. Patient sera 
were used instead of umbilical cord blood sera for epitope mapping in order to check the response of strongly 
immunized patients. The key findings of this publication are that both peptides are common and conserved 
between pathogenic and non-pathogenic strains (Fig. 5); both epitopes are specifically recognized by sera from 
GBS+ patients (Fig. 6) and patients with autoimmune disease (Fig. 7) which excludes their usage as vaccine 
antigens.
A potential vaccine epitope should be specific for the pathogenic strain and not to non-pathogenic strains to 
avoid cross-reactivity, especially with bacteria naturally present in the body. The level of sequence similarity of 
both peptides was investigated among pathogenic strains expressing the protein as a moonlight protein, strains 
most prevalent in gut flora, with human and mouse GAPDH sequences (Fig. 5). P9 and P10 show high level of 
similarity between pathogenic and healthy gut flora. This may indicate that this part of the protein is responsible 
for the function of the protein and therefore stays conservative. So far there is only one well known active site 
in GAPDH which is localized around Cys149 and His17631 and falls far from the localization of P9 and P10. These 
sequences may have another functionalities for example maintain protein structure or take part in interactions 
with other proteins. GAPDH as a moonlighting protein comes into interaction with other proteins both intracel-
lular and extracellular, including plasminogen and mucin32–34. Moreover, we still do not know how the GAPDH 
is maintained on the surface of the bacterial cell where it fulfills the above-mentioned adhesion functions. The 
contribution of such interactions of both peptides should be investigated.
We found out that umbilical cord blood sera isolated from patients with GBS infection recognize specifically 
P9 and P10 (Fig. 6). GBS GAPDH is already well described in the literature33,35. In this pathogen GAPDH is an 
extracellular virulence factor that induces IL-10 expression which has immunosuppressive effect on the host 
by impairing neutrophil recruitment to infected sites36. Maternal vaccination with GBS GAPDH protects new-
borns against infection. Antibodies against P9 and P10 might have protective properties which should be further 
investigated. However, before administration of such a vaccine to a human subject the possible autoimmunizing 
properties should be taken into account.
The GAPDH-connected situation gets even more complicated when probiotic bacteria are added into the 
equation. The protein is not only found on the surface of microbiome bacteria but also shows immunoreactivity 
which was reported in our previous studies37. We identified GAPDH among many other immunoreactive moon-
lighting proteins in Bifidobacterium longum ssp. longum CCDM 372. The same protein was found on the surface 
of numerous lactic acid probiotic bacteria: L. acidophilus, Lactobacillus amylovorus, L. crispatus, Lactobacillus 
gallinarum, L. gasseri, L. johnsonii, Lactobacillus paracasei, L. rhamnosus and L. lactis in which it was associated 
with pH-dependent adhesion to plasminogen and mucin. Our preliminary data show that sera from rabbits 
immunized with Lactobacillus johnsonii 14238 does not specifically recognize P10 and P9 but other peptides from 
GAPDH sequence exhibit higher immunoreactivity (data not shown). It might be explained by that immune sys-
tems from different organisms elicit alternative antibody population to the same antigen20 or that probiotic strains 
modulate immune response in such way that antibodies of different specificity are produced.
What we are particularly interested in is the high degree of conservation of P9 and P10 sequences in very 
distant phylogenetic species such as CD and human or mouse. Despite GAPDH whole protein homology about 
44.5% for human 10 out of 16 amino acids in sequence P9 are preserved and 8 out of 16 amino acids in P10 
sequence, with control peptide P5 only 6 amino acids out of 16 (Fig. 5). For this reason, we have examined the 
possible relationship between these sequences and autoimmunity which revealed anti-GAPDH autoantibodies 
specific for sequences existing in peptide 9. These sequences were reported in systemic lupus erythematosus15 and 
were found in cerebrospinal fluid of patients with multiple sclerosis14. We have shown that pooled sera collected 
from patients with autoimmune disease (Graves disease, n = 10) are more reactive with both peptides tested as 
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compared to healthy controls (n = 10). Serum samples from two out of three individual patients showed greater 
immunoreactivity with P9 than healthy controls.
Peptides from microorganisms, that are sufficiently similar to the host antigens, can activate autoreactive T 
cells. This phenomenon is called molecular mimicry39,40. In particular, inflammation and recurrence of infec-
tion, which is very common in CDI, can lead to localized activation of antigen presenting cells and to increased 
processing and presentation of own antigens present in the site of inflammation. An example of an autoimmune 
disease caused by acute infection is Guillain-Barré syndrome, a disease that attacks various organs including the 
central nervous system. The etiological factor of the disease is Campylobacter jejuni, the leading cause of diarrhea 
in the United States. C. jejuni induces antibodies that cross-react with peripheral nerve antigens41. We find an 
analogy to CDI in the above-mentioned phenomenon. Strong infection such as CDI may have more effect on 
the host immune system than we thought. Probably the immune system mobilizes all the strengths to clear off 
the infection but at the same time it can lead to subsequent serious complications. Antibodies that target host 
proteins or natural bacterial flora may appear during strong inflammation caused by CD, which later result in the 
appearance of an autoimmune disease. It seems that other pathogens may affect the system in similar way since 
we demonstrated a cross-reaction between P9 and P10 with sera collected from GBS+ patients, but in this case we 
have not done limited dilution of antibody titer. A massive infection like CDI elicits a burst of antibodies which 
cannot be compared with the yield of umbilical cord transport or the level of antibodies induced by gut flora in 
which case it can have protective or desensitizing role.
Autoimmune response as a result of vaccination albeit very rare should be taken into consideration when 
developing a new vaccine. Several cases described the relationship between vaccination against hepatitis B and 
demyelization, which can lead to multiple sclerosis42,43. There have also been isolated cases linking hepatitis B vac-
cine and rheumatoid arthritis44. Another study show that after infection with Borrelia burgdorferi, some vaccines 
are more likely to develop chronic, poorly responsive Lyme arthritis associated with high levels of antibody to the 
vaccine antigen OspA, in serum and synovial fluid45.
Finding suitable bacterial vaccine antigen is a complicated process due to multiple mechanisms used by path-
ogens to avoid immune system and because of the possibility of eliciting an immune response against own anti-
gens or antigens of own bacterial flora. One of the recently proposed protein is GAPDH which is essential and 
conserved. Above experiments show how to verify the suitability of a protein as a vaccine antigen using GAPDH 
from Clostridium difficile as an example. We demonstrated that infection with this pathogen may cause humoral 
response to produce anti-GAPDH antibodies which are cross-reactive with GAPDH sequences of other patho-
gens and/or healthy gut microflora. Furthermore, CD GAPDH specific epitopes may induce antibodies directly 
against self-antigens leading to autoimmunity which is why it should not be used in a vaccine as a whole protein. 
However, it does not preclude the possibility that GAPDH yet contains other epitopes that might be utilized as 
antigen to produce robust and protective vaccine but further investigation is warranted. As a result of the anal-
ysis we suggest that using GAPDH as a vaccine antigen should be thoroughly investigated in the case of each 
pathogen.
Materials and Methods
Blood sera. Human peripheral blood sera. Blood sera (pooled n = 15) from patients diagnosed with CDI 
(based on ≥3 loose stools in 24 hours, abdominal pain, fever and positive laboratory results for presence of 
GDH - glutamate dehydrogenase and CD toxins A and B (C. Diff Quik Chek Complete; TECHLAB, Inc, USA)46) 
were obtained from 4th Military Hospital in Wroclaw, written approval was received from the Medical Ethics 
Commission of the Medical University of Wroclaw (no. KB-631/2015) and were conducted in accordance with 
the Helsinki Declaration, 1975. Samples were obtained with patients who signed the written informed consent.
Blood sera from patients with autoimmune disorders (n = 10) were obtained from unrelated patients suffer-
ring from Graves’ disease (GD). Samples were obtained with patients who signed the written informed consent. 
The initial diagnosis of GD was confirmed by routine clinical and laboratory tests, including a history of thyro-
toxicosis, diffuse goiter, suppressed serum TSH, elevated free thyroxine, and/or free triiodothyronine levels, as 
well as high anti-thyroid peroxidase or TSH-binding inhibiting immunoglobulin titers. The ophthalmological 
examination, together with the severity and ocular activity, was performed at the time of blood collection47. Three 
individual patient serum samples obtained from not smoking females with sporadic incidence of GD and Graves’ 
orbitopathy (GO) were selected for separate analysis. Two of them presented active GO, and one - severe GO at 
the day of blood sampling. Sera used as healthy controls (pooled, n = 21) were collected from apparently healthy 
volunteers. Performed experiments were approved by the Medical Ethics Committee of the Medical University of 
Wroclaw (approval No KB-322/2010) with patients’ and healthy volunteers written informed consent and were 
conducted in accordance with the Helsinki Declaration, 1975.
Human umbilical cord blood sera. Human umbilical cord blood sera (pooled n = 10) used for immunoreac-
tive protein screening were obtained from the Obstetric Clinic of the Medical University of Wroclaw (approval 
no. KB-882-2012), collected from healthy women. Samples were obtained with patients who signed the written 
informed consent and were conducted in accordance with the Helsinki Declaration, 1975. The same sera were 
used as healthy controls for GBS experiment.
Umbilical cord blood sera for cross-reactivity testing with GBS were obtained from pregnant women with 
confirmed genital tract and/or anus colonization by Streptococcus agalactiae. The inclusion criteria were: preg-
nant women in the third trimester between 18 and 40 years of age; a written statement of consent to partici-
pate in the study. Sera characterization: KP15 GBS+, Hashimoto disease; KP20 GBS+, hypothyroidism; KP 27 
GBS+, diabetes; KP17 GBS−, Hashimoto disease, diabetes; KP31 GBS−, Von Willebrand disease. The study 
was approved by Jagiellonian University Bioethical Committee decision no. KBET/153/B/2014. Samples were 
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obtained with patients who signed the written informed consent and were conducted in accordance with the 
Helsinki Declaration, 1975.
Bacterial strains and culturing conditions. Clostridium difficile Cd20 strain was isolated from a stool 
sample of a 71 year old patient diagnosed with pseudomembranous colitis, according to clinical symptoms, lab-
oratory (as described above) and colonoscopy results. Stool sample was cultured anaerobically at least for 48 h 
on selective CD media [CDIF - chromID™ C. difficile and CLO - Columbia agar with cycloserine, cefoxitin and 
amphotericin B (bioMerieux, Mary L’Etoile, France)] incubated for at least 48 hours in a temperature of 37 °C 
under anaerobic conditions in the anaerobic chamber. Colonies were examined for the characteristic horse odor, 
yellow-green fluorescence in the UV light and Gram staining. Suspected colonies were identified by the ANC card 
in an automatic system - VITEK 2 Compact. Toxin production (toxins TcdA, TcdB and binary toxins) was deter-
mined by molecular methods, and ribotyping was performed, as previously described46,48. CD strain belongs to 
ribotype 027, and was resistant to moxifloxacin, ciprofloxacin, erythromycin and imipenem, as was demonstrated 
by E-tests46. Strain was deposited in Polish Collection of Microorganisms as PCM 2826. The isolate was cultured 
in BHI with addition of 0.05% L-cysteine hydrochloride at 37 °C in anaerobic conditions for 48 h. Each time 
culture was inspected in terms of microbiological content. Cells were harvested by centrifugation in (6000 × g 
for 15 min) and washed two times in phosphate-buffered saline pH 7,4 (PBS) before used in further experiments.
Surface proteins isolation. Surface proteins of CD were isolated using 1 M LiCl method which offers sur-
face protein isolation in mild conditions19. 1 g of PBS-washed bacterial mass was suspended in 7 ml of freshly 
prepared 1 M LiCl. The mixture was incubated for 1 h in room temperature with shaking. After centrifugation 
(6000 × g for 5 min) supernatant was collected and dialyzed against MQ water for at least 48 h and concentrated 
on filters MWCO = 10 000 Da. The concentration of surface proteins was estimated using Pierce™ BCA Protein 
Assay Kit (Thermo Fisher Scientific). Prepared samples were aliquoted and stored at −20 °C.
SDS-PAGE and Western blotting. SDS-PAGE was performed according to Laemmeli49 using large size 
gels 18 × 16 cm with 1.5 mm thick combs, resolved in SE600 Standard Dual Cooled Vertical Unit. Each time equal 
amount of proteins was loaded on the 5–12.5% gels (30 µg per well) according to Laemmli49, Tris-Glycine-SDS 
was used as running buffer. Each time a double-stained Precision Plus Protein Dual Color protein ladder was 
loaded on the gel (Bio-Rad). Gels were run for about 5 hours at 150 V with cooling. Protein samples for silver 
staining and Western blotting were run on one gel which was cut into two parts after electrophoresis. Silver stain-
ing was performed according to Shevchenko with changes50. Gel was fixed in 5% acetic acid and 50% methanol 
for 60 min, washed in 50% methanol and MQ water, incubated 3 min in 0.02% sodium thiosulfate, washed again 
with MQ water, incubated for 45 min in 0.15% silver nitrate washed with MQ water, the reaction was induced by 
2% sodium carbonate, and 0.04% formaldehyde. The reaction was stopped by 5% acetic acid. The second part of 
the gel was incubated in transfer buffer (10 mM Tris-HCl, 150 mM glycine, 20% methanol, pH 8.3) for 30 min and 
transferred into polyvinylidene difluoride membrane Immobilon-P using Trans-Blot® SD Semi-Dry Transfer 
Cell. Transfer condition was 25 V for 60 min. The efficiency of transfer was tested by silver staining the remaining 
gel. Western blotting was done as previously37. Membrane with transferred proteins was blocked in 1% bovine 
serum albumin in Tris-buffered saline with Tween 20 (TBST, 20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 
20) for 1 h in RT. We used umbilical cord blood sera for immunoblotting, dilution 1:100 in TBST with 0.1% BSA, 
incubated overnight at 4 °C. Membrane was washed three times in TBST 10’ with mixing and incubated with sec-
ondary antibodies, anti-human IgG conjugated with AP diluted 1:10 000, 1 h in RT. Membrane was washed three 
times in TBST 10’ with mixing and reaction was induced by adding solution containing nitro blue tetrazolium 
and 5-bromo-4-chloro-3-indolyl phosphate in TBST with MgCl2. Reaction was developed until bands become 
visible and then stopped by washing in MQ water. Membrane was documented using PXi imaging system using 
protocol for visible blots.
Protein identification. Protein bands cut from the gel were identified using protein digestion with trypsin 
followed by separation of peptides mixture by liquid chromatography and mass spectrometry of the peptides and 
peptide fragments by the mass spectrometer LC-MS-MS/MS Orbitrap. Peptide molecular masses were compared 
with the protein sequence database (NCBI, UniProt database) using MASCOT program (http://www.matrixsci-
ence.com/). All searches were performed against the database for Peptoclostridium difficile.
Bioinformatic analysis. GAPDH protein structure modeling. Since there is no crystal structure for 
GAPDH from CD the structure model was built using homological sequence. The sequence of the highest homol-
ogy (74.55% identity) with known crystal structure was found by BLAST - Streptococcus agalactiae GBS GAPDH 
(PDB 5jyf.1.A, crystal structure obtained using x-ray diffraction at 2.62 Angstrom resolution51). The model was 
built by SWISS MODEL workspace52 and used for selecting potential epitopes.
GAPDH amino acid sequence analysis. The sequence variation between 50 different CD strains, including tox-
igenic and nontoxigenic, was performed using Clustal Omega53. The same tool was used to align CD GAPDH 
sequence with sequences of the same protein from other pathogenic and nonpathogenic strains. Subcellular local-
ization was predicted using PSORTb v3.0 (Gram-positive bacteria)54. It employs SCL predictors using 5-fold cross 
validation and performs proteomics analysis which results in most precise localization predictor.
GAPDH epitope prediction. Linear B-cell epitopes were predicted using two online tools BCPred and SVMTrip. 
Each time linear 16-aa epitopes were predicted. BCPred predict linear B-cell epitopes using Support Vector 
Machine classifiers that use string kernels55. SVMTrip is a method in which Support Vector Machine (SVM) 
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has been utilized by combining the Tri-peptide similarity and Propensity scores (SVMTriP) in order to achieve 
the better prediction performance56. T lymphocyte epitope mapping tools were also used to designate potential 
epitopes (http://crdd.osdd.net/raghava/mhc/index.html).
Results from structure analysis and epitope prediction tools were combined into twenty 16-mer amino acid 
epitopes selected for chemical synthesis on plastic pins.
Immune epitope database and autoantigen search. Immune Epitope Database and Analysis Resource (IEDB, 
www.iedb.org)57 was used for searching for known epitopes within analyzed peptides. We were looking for 
epitope content with no less than 70% identity. The search was not restricted to any host, assay, MHC type nor 
disease. AAgAtlas database 1.0 was used for autoantigen search (http://biokb.ncpsb.org/aagatlas). This database 
was used for browsing of autoantigens and associated diseases.
Epitope mapping. Epitope synthesis. Selected peptides were synthesized using Geysen (PEPSCAN) pro-
cedure with changes20,58. Peptides were synthesized on polyethylene pins (MIMOTOPES, Clayton, Victoria, 
Australia) in a 96 well plate by adding one amino acid to each pin during one coupling reaction. F-moc amino 
acid derivatives with blocked side groups were used for the synthesis. Pins underwent deprotection in 20% pip-
eridine in dimethylformamide (DMF) before the addition of each amino acid. Then, after washing in DMF and 
methanol dried pins were subjected to the coupling reaction. The reaction mixture consisted of 60 mM of blocked 
amino acid, 60 mM diisopropylcarbodiimide and 65 mM N-hydroxybenzotriazole in DMF. 0.5 mM bromophenol 
blue were added to monitor the progress of the reaction. The coupling reaction was carried out for at least 4 hours 
at room temperature in a sealed vessel. After washing and another pin deprotection it was subjected to the next 
coupling reaction until a full-length peptide was obtained. The full length pin-bound peptide was subjected to the 
side group’s removal reaction with 2.5% anisole and 2.5% dithioethane in trifluoroacetic acid. Peptides were then 
washed in methanol, 0.5% acetic acid and methanol again, dried and stored at −20° until used.
Enzyme-Linked Immunosorbent Assay (ELISA). Epitopes were mapped by ELISA performed on pin-bound pep-
tides using sera from different groups as previously20. Before the assay, pins were equilibrated in TBS-T for 10 min. 
Pins were blocked for 1 h in RT with 1% bovine serum albumin. Sera were used in 1:1000 dilution in TBS-T, sec-
ondary antibodies anti-human IgG conjugated with AP were used in 1:10000 dilution (Sigma-Aldrich). Color 
reaction was performed by using Alkaline Phosphatase Yellow Liquid Substrate System for ELISA. All assays were 
performed at least in triplicate. Bound antibodies were detached by 10 min sonication in disruption buffer, pH 
7.2 heated to 60 °C consisting of 1% sodium dodecyl sulfate, 0.1% 2-mercaptoethanol and 0.1 M Na3PO4. After 
washing in water and methanol pins were dried and stored at 4 °C until further used.
Statistical analysis. All figures show data from at least three independent measurements, means with SD, 
data analyzed with 2way ANOVA. Statistical analysis was performed using GraphPad Prism version 7.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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